shutterstock_1492661771_ricochet64-1
ricochet64 / Shutterstock.com
11 May 2021Big PharmaMuireann Bolger

Mylan fails to void MSD diabetes treatment patent at PTAB

MSD, known as Merck in the US and Canada, has prevailed against a bid by Mylan Pharmaceuticals and other generic drug makers to invalidate a diabetes treatment patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

More on this story

Americas
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.

More on this story

Americas
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.
Americas
18 July 2018   US-based biopharmaceutical company AbbVie entered into a patent licensing agreement with generics company Mylan yesterday.